Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» larotrectinib
larotrectinib
Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer
Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer
Endpoints
FDA
larotrectinib
Bayer
Loxo Oncology
oncology
personalized medicine
Flag link:
Loxo's targeted therapy holds up to Roche challenge
Loxo's targeted therapy holds up to Roche challenge
Biopharma Dive
Roche
entrectinib
Loxo Oncology
Ignyta
Bayer
larotrectinib
Flag link:
3 Biotechs Awaiting FDA Approval Decisions
3 Biotechs Awaiting FDA Approval Decisions
Motley Fool
FDA
TherapeuticsMD
TX-001HR
AcelRx
Dsuvia
Loxo Oncology
larotrectinib
Flag link:
FDA starts speedy review of Loxo’s site-agnostic cancer drug larotrectinib
FDA starts speedy review of Loxo’s site-agnostic cancer drug larotrectinib
Fierce Biotech
FDA
Loxo Oncology
Bayer
metastatic solid tumors
larotrectinib
Flag link:
[video]Is Loxo Oncology's Deal With Bayer Bad News?
[video]Is Loxo Oncology's Deal With Bayer Bad News?
Motley Fool
Loxo Oncology
Bayer
larotrectinib
Flag link:
Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?
Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?
Motley Fool
Loxo Oncology
larotrectinib
Flag link:
Loxo Oncology Shares Rally, Despite Diluting Investors
Loxo Oncology Shares Rally, Despite Diluting Investors
Motley Fool
Loxo Oncology
larotrectinib
Flag link:
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
Forbes
cancer
oncology
larotrectinib
Loxo Oncology
clinical trials
patients
Flag link:
Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval
Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval
Endpoints
Loxo Oncology
ASCO 2017
biomarkers
LOXO-101
larotrectinib
Flag link: